Skip to main navigation Skip to search Skip to main content

A trial to evaluate the effect of the sodium–glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

  • on behalf of the DAPA-HF Committees and Investigators

Research output: Contribution to journal › Article › peer-review

327   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'A trial to evaluate the effect of the sodium–glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases